MOAT
Quality FactorVanEck Morningstar Wide Moat ETF
VanEck · Tracks Morningstar Wide Moat Focus Index · Inception Apr 24, 2012
Composite score
Based on a 0.46% expense ratio.
Based on $11.62B in net assets.
Top-10 holdings represent 26.8% of net assets.
Quality Factor base · ETF wrapper · 1.32% TTM yield.
The composite is a weighted average of the four core sub-scores above (cost, tax efficiency, liquidity, concentration). Missing sub-scores fall back to the per-category median when the category has at least 50% data coverage, so funds without (e.g.) parsed N-PORT holdings aren't accidentally boosted by renormalization. Tracking quality is shown where computable but isn't currently part of the composite weighting. See methodology for formulas, the tracking-quality partial-coverage rationale, and the dimensions we deliberately don't score (methodology v0.5.1).
Use MOAT in our tools
Tool · Cost
Compare MOAT's fee against another fund
Compounds the 0.46% expense ratio against a peer over decades.
Tool · Overlap
Compare MOAT's holdings with peers
Pairwise holdings heatmap, pre-loaded with similar Quality Factor funds.
Tool · TLH
Find a tax-loss harvesting partner for MOAT
Ranks every catalog fund by holdings overlap, flags wash-sale risk.
Tool · Placement
Where should this fund live across your accounts?
Asset-location optimizer — places each fund in taxable / tax-deferred / Roth.
Top holdings
| # | Holding | Weight |
|---|---|---|
| 1 | Bristol-Myers Squibb Co | 2.90% |
| 2 | Mondelez International Inc | 2.74% |
| 3 | Constellation Brands Inc | 2.74% |
| 4 | Kenvue Inc | 2.67% |
| 5 | Airbnb Inc | 2.64% |
| 6 | Zoetis Inc | 2.62% |
| 7 | Brown-Forman Corp | 2.62% |
| 8 | Zimmer Biomet Holdings Inc | 2.62% |
| 9 | Fortinet Inc | 2.61% |
| 10 | Clorox Co/The | 2.61% |
Compare MOAT with another fund
Or skim the closest-overlap funds below.
Similar ETFs by holdings overlap
Open MOAT at a brokerage
Affiliate links — opening an account through these earns PlainIndex a one-time referral. Scoring is computed before any affiliate consideration; see our methodology and funding disclosure.